Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Sahil Sekhon; Caleb Jeon; Mio Nakamura; Di Yan; Ladan Afifi; Tina Bhutani; Ethan Levin

doi:10.2147/PTT.S129792

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis

Psoriasis (Auckl). 2017 Nov 16:7:65-72. doi: 10.2147/PTT.S129792. eCollection 2017.

Authors

Sahil Sekhon¹, Caleb Jeon¹, Mio Nakamura¹, Di Yan¹, Ladan Afifi¹, Tina Bhutani¹, Ethan Levin¹

Affiliation

¹ Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.

Abstract

Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

Keywords: IL-17; anti-IL-17; biologics; ixekizumab; psoriasis.

Publication types

Review